In another randomized, open-label, phase two trial, comparing continuous versus intermittent BRAF and MEK inhibition in patients with BRAF-mutated melanoma, Algazi et al. [60] reported that continuous dosing was associated with a statistically significant improvement in median PFS compared with intermittent dosing (9.0 months versus 5.5 months, p = 0.064, pre-specified two-sided α = 0.2). The gene discussed is BRAF; the disease is melanoma.